| Abstract:Objective To explore the applied significance of plasma tissue factor pathway inhibitor-1(TFPI-1) in differential diagnosis, disease conditions evaluation, and therapeutic observation of lung cancer patients. Methods Plasma levels of TFPI-1, antithrombin (AT), and D-dimer (D-D) were measured in 68 non-small cell lung cancer (NSCLC) patients, 32 benign lung disease patients, and 40 healthy individuals, and the correlation was analyzed between the levels of TFPI-1 and AT, as well as D-D. The alternation of the three indicators was observed before and after treatment. Receiver operating characteristic (ROC) curve was used to analyze their diagnostic efficiency in differential diagnosis, prediction of deep venous thrombosis (DVT) and metastatic spread of NSCLC. Results In NSCLC group, levels of TFPI-1 and AT were significantly lower,D-D level was markedly higher, than those in disease control group and healthy control group (P=0.000). There was positive and negative correlation between levels of TFPI-1 and AT as well as D-D, respectively (r=0.789 and -0.822, P<0.01). In DVT group and metastatic spread group, TFPI-1 levels were significantly lower than those in non-DVT group and non-metastatic spread group (P=0.000). The cutoff value of TFPI-1 in differential diagnosis, prediction of DVT and metastatic spread of lung cancer was 52.3, 58.2, and 64.3ng/ml,the area under ROC curve was 0.884(95% CI:0.811-0.958), 0.957(95% CI:0.919-0.996), and 0.856(95% CI:0.774-0.938)(P<0.05),the sensitivity was 86.76%, 89.5%, and 82.1%,and the specificity was 83.3%, 85.5%, and 82.5%, respectively. Compared with before treatment group, the levels of TFPI-1 and AT significantly increased, but D-D level decreased in after treatment group (P=0.000). TFPI-1 levels continuously increased in the four observed NSCLC patients since treatment started, however, just after treatment of at least 6 days, the levels of AT may start increasing and D-D decreasing. Conclusion There is important significance of plasma TFPI-1 in differential diagnosis, disease conditions evaluation, and therapeutic observation of lung cancer patients. |
